Skip to main content

Table 3 Adverse events related to the study drug (all cycles)

From: Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

 

Planned dose level, mg/m2

All

(N = 31)

 

1.5

3

6

8.4

10

12

 
 

(n = 1)

(n = 1)

(n = 4)

(n = 12)

(n = 7)

(n = 6)

  

Adverse event, n

G3

G4

G3

G4

G3

G4

G3

G4

G3

G4

G3

G4

G3

G4

Non-haematological

              

  Fatigue

3

2

5

  Diarrhoea

1

1

3

5

  Haematuria

1

1

  Febrile neutropenia

1

1

  Dysuria

1

1

Haematological

              

  Neutropenia

1

2

1

2

  Anaemia

1

1

Days to neutrophil nadir, median (range)

17

22

32–32

31–31

17–22

18–18

21–22

17–32

Median neutrophil nadir, x 10 9 /l (range)

2.3

2.2

2.2

3.1

2.3

 

(3.4–3.4)

(1.8–1.8)

(1.4–9.0)

(0.9–5.0)

(1.2–5.7)

(0.2–7.3)

(0.2–9.0)

  1. G3 Grade 3, G4 Grade 4.